| Indicators | Browse All

Aptevo Therapeutics Inc. (APVO)

Healthcare | Biotechnology | Seattle, United States | NasdaqCM
1.73 USD -0.11 (-5.789%) ⇩ (Oct. 13, 2026, 3:42 p.m. EDT)

Short-term:⯪☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take ↕ | Oct. 10, 2026, 6:50 a.m. EDT

The immediate outlook is severely bearish, driven by a crushing multi-year price collapse where the asset has lost virtually all its value over the last decade, with four consecutive years of negative returns ending recently. This structural deterioration suggests the market has permanently reassessed the business quality downward, rendering any short-term bounce highly speculative and likely a continuation of the downtrend. Fundamentally, the company is in deep distress with negative free cash flow, negative returns on equity and assets, and no earnings visibility, as indicated by negative forward estimates. There is no dividend income to offset these massive capital losses. While analyst targets suggest a theoretical recovery to much higher prices, the current reality of a failing balance sheet and a stock trading at a fraction of book value due to insolvency risks makes this a clear avoid for both short-term traders and long-term investors.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.491622
AutoETS0.496428
AutoARIMA0.506917
MSTL0.509890

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 30%
H-stat 68.51
Ljung-Box p 0.000
Jarque-Bera p 0.116
Excess Kurtosis -1.50
Attribute Value
Sector Healthcare
Debt to Equity Ratio 69.674
Market Cap 3,131,672
Trailing P/E 0.03
Forward P/E -0.17
Beta 1.68
Website https://aptevotherapeutics.com

Info Dump

Attribute Value
52 Week Change -0.9374233
Address1 2,401 4th Avenue
Address2 Suite 1050
All Time High 68,020,448.0
All Time Low 1.37
Ask 2.31
Ask Size 2
Average Daily Volume10 Day 46,800
Average Daily Volume3 Month 94,060
Average Volume 94,060
Average Volume10Days 46,800
Beta 1.681
Bid 1.32
Bid Size 2
Book Value 4.257
City Seattle
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.73
Current Ratio 2.081
Custom Price Alert Confidence HIGH
Date Short Interest 1,790,726,400
Day High 1.79
Day Low 1.7
Debt To Equity 69.674
Display Name Aptevo Therapeutics
Dividend Date 1,585,267,200
Dividend Yield 0.0
Earnings Timestamp End 1,754,915,400
Earnings Timestamp Start 1,754,483,400
Ebitda -26,689,000
Ebitda Margins 0.0
Enterprise To Ebitda 0.085
Enterprise Value -2,279,042
Eps Current Year -16.02
Eps Forward -10.4
Eps Trailing Twelve Months 66.96
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 15
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 206 838 0503
Fifty Day Average 2.41554
Fifty Day Average Change -0.68553996
Fifty Day Average Change Percent -0.28380403
Fifty Two Week Change Percent -93.74233
Fifty Two Week High 30.06
Fifty Two Week High Change -28.33
Fifty Two Week High Change Percent -0.94244844
Fifty Two Week Low 1.37
Fifty Two Week Low Change 0.36
Fifty Two Week Low Change Percent 0.26277372
Fifty Two Week Range 1.37 - 30.06
Financial Currency USD
First Trade Date Milliseconds 1,469,021,400,000
Float Shares 1,696,717
Forward Eps -10.4
Forward P E -0.16634616
Free Cashflow -15,564,750
Full Exchange Name NasdaqCM
Full Time Employees 33
Fullday Change -0.1063
Fullday Change Percent -5.788814
Fullday Price 1.73
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.04153
Held Percent Institutions 0.02884
Implied Shares Outstanding 1,810,215
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,767,052,800
Last Split Factor 1:18
Long Business Summary Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Long Name Aptevo Therapeutics Inc.
Market us_market
Market Cap 3,131,672
Market State REGULAR
Max Age 86,400
Message Board Id finmb_331280020
Most Recent Quarter 1,782,777,600
Net Income To Common -26,505,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 3,421,306
Number Of Analyst Opinions 2
Open 1.79
Operating Cashflow -25,343,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 206 838 0500
Previous Close 1.8363
Price Eps Current Year -0.10799001
Price Hint 4
Price To Book 0.40638947
Profit Margins 0.0
Quick Ratio 1.888
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.1063
Regular Market Change Percent -5.788814
Regular Market Day High 1.79
Regular Market Day Low 1.7
Regular Market Day Range 1.7 - 1.79
Regular Market Open 1.79
Regular Market Previous Close 1.8363
Regular Market Price 1.73
Regular Market Time 1,791,920,564
Regular Market Volume 84,155
Return On Assets -1.11494
Return On Equity -4.20342
Sand P52 Week Change 0.17502642
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 1,810,215
Shares Percent Shares Out 0.066
Shares Short 119,457
Shares Short Previous Month Date 1,788,134,400
Shares Short Prior Month 118,188
Short Name Aptevo Therapeutics Inc.
Short Percent Of Float 0.0699
Short Ratio 0.62
Source Interval 15
State WA
Symbol APVO
Target High Price 30.0
Target Low Price 21.0
Target Mean Price 25.5
Target Median Price 25.5
Total Cash 9,797,000
Total Cash Per Share 5.437
Total Debt 4,209,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps 66.96
Trailing P E 0.02583632
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 4.94344
Two Hundred Day Average Change -3.21344
Two Hundred Day Average Change Percent -0.6500413
Type Disp Equity
Volume 84,155
Website https://aptevotherapeutics.com
Zip 98,121